利民股份(002734.SZ):收購威遠生化、威遠藥業及新威遠各5%股權完成工商變更登記
格隆匯 8 月 13日丨利民股份(002734.SZ)公佈,公司於2020年7月30日召開第四屆董事會第十六次會議,審議通過《關於公司收購控股子公司少數股東股權的議案》。公司決定使用自有或自籌資金6400萬元收購嘉興金榆新威股權投資合夥企業(有限合夥)持有的河北威遠生物化工有限公司(“威遠生化”)、河北威遠藥業有限公司(“威遠藥業”)及內蒙古新威遠生物化工有限公司(“新威遠”)各5%的股權。
近日,威遠生化、威遠藥業和新威遠各自已完成工商核准變更登記和章程備案手續,並取得了行政審批部門出具的《備案通知書》。完成工商變更登記後,標的股權過户完成,公司分別直接持有威遠生化、威遠藥業和新威遠各65%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.